Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

5.38USD
20 Jul 2018
Change (% chg)

$0.17 (+3.26%)
Prev Close
$5.21
Open
$5.17
Day's High
$5.41
Day's Low
$5.16
Volume
313,147
Avg. Vol
445,464
52-wk High
$7.21
52-wk Low
$0.94

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $453.92
Shares Outstanding(Mil.): 87.13
Dividend: --
Yield (%): --

Financials

  ARQL.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -0.36 -- --
ROI: -82.63 -3.65 13.18
ROE: -211.08 -5.62 15.09

BRIEF-Arqule Files Prospectus Related To Seconday Offering Of Up To 10.6 Mln Shares

* ARQULE INC FILES PROSPECTUS RELATED TO OFFERING UP TO 10.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source http://bit.ly/2IOmvpZ Further company coverage:

May 17 2018

BRIEF-Arqule Reports Q1 Loss Per Share Of $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

May 07 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

Apr 17 2018

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 05 2018

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

Feb 07 2018

Earnings vs. Estimates